Announcements Trials

Browse Landscape

Phase

Status

Completed 95 Terminated 37 Unknown 12 Withdrawn 4 Active not recruiting 3 Recruiting 2 Suspended 1 Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1 Lymphoid 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 1

Interventions

Specimen Handling 34 Magnetic Resonance Spectroscopy 22 Biopsy 20 Cyclophosphamide 16 Nivolumab 10 Paclitaxel 9 Cisplatin 9 Gemcitabine 8 Bevacizumab 8 venetoclax 7 Vincristine 7 Prednisone 7 Doxorubicin 7 Azacitidine 7 pembrolizumab 6 Radiotherapy 6 Radiosurgery 6 Fluorouracil 6 Etoposide 6 Drug Therapy 6 Docetaxel 6 Taxes 5 Surgical Procedures, Operative 5 Rituximab 5 Oxaliplatin 5 Irinotecan 5 Everolimus 5 Capecitabine 5 fludarabine phosphate 4 fludarabine 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Suspended × Alemtuzumab × Clear all

NCT01982175 2022-06-21

CLL004

Shanghai Zhangjiang Biotechnology Limited Company

Phase 2 Suspended

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡